Articles
Sorrel™

Sorrel Wearable Injection Solution -
An Interview With Dr. Andrei Yosef

dr-andrei-yosef-s
Dr. Andrei Yosef
OnDrugDelivery
September 18, 2020

Andrei Yosef is Chief Executive Officer of Sorrel Medical, an Eitan Medical company focused on the development and manufacture of wearable drug delivery solutions for easy and efficient self-administration. He is a recognised expert in drug delivery device technology and high-end development processes, having served in several executive positions at Q Core Medical – a developer of smart infusion systems for hospital and ambulatory care settings. Dr. Yosef holds a PhD in Biomedical Engineering and an MA in Mechanical Engineering, both from the Technion – Israel Institute of Technology. In this exclusive interview with ONdrugDelivery, Dr Yosef discusses Sorrel’s differentiated electro-mechanical, connected wearable injection platform, and two exciting recent milestones for the company, the opening of a state-of-the-art manufacturing facility and the signing of a significant partnership with a large pharmaceutical company.

Q: The wearable injectors space is crowded. Please provide an overview of Sorrel Medical’s wearable device platform. How it is differentiated from other wearable injectors, and how does it help Sorrel’s partners to differentiate their therapeutic products?

Figure 1: Sorrel Medical’s wearable drug delivery device platform.

A:  Sorrel’s wearable drug delivery platform is designed to provide a patient-centric and partner- focused solution for the self-administration of large-volume and high-viscosity medications. The prefilled and preloaded device configuration encourages adherence to treatment therapies and reduces the risk of medication errors. Being primary container-agnostic enables us to collaborate with multiple pharmaceutical partners to meet specific drug delivery requirements. Sorrel devices utilise an electro-mechanical pumping mechanism for accurate and controlled drug delivery. To overcome the inherent challenge of maintaining sterility in preloaded devices, we have implemented first-of-its-kind UV LED technology for disinfection at point-of-care, disinfecting the point of engagement between the primary container and the device’s fluid path. Additionally, we have proprietary technology in place which provides a unique solution for drawing medication directly from a vial, while remaining prefilled and preloaded. This saves our partners significant time and risk, as our devices conform to the primary container of their choice

 

Share:

We use cookies to enhance site navigation, analyze website usage, assist in our third parties’ marketing efforts, and otherwise. By using this site you agree to our use of cookies. For more information please read our Privacy Statement.